chrisvoncsefalvay/vaers-outcomes huggingface dataset:
swelling of his eyes; swelling of his face; "Bumps" on his body; This spontaneous case was reported by a consumer and describes the occurrence of EYE SWELLING (swelling of his eyes), SWELLING FACE (swelling of his face) and SWELLING ("Bumps" on his body) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 30-Apr-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced EYE SWELLING (swelling of his eyes), SWELLING FACE (swelling of his face) and SWELLING ("Bumps" on his body). At the time of the report, EYE SWELLING (swelling of his eyes), SWELLING FACE (swelling of his face) and SWELLING ("Bumps" on his body) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter. No treatment information was provided.
interchange of vaccine products; COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP) from product quality group. The reporter is the patient.  A 54-year-old patient received BNT162b2 (BNT162B2), on 21Jul2022 at 13:15 as dose 4 (booster), single (Lot number: FJ4991) at the age of 54 years, in left arm for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), on 10Feb2021 at 14:30 as dose 1, single (Lot number: 038K20A), in left arm, on 22Mar2021 at 12:00 as dose 2, single (Lot number: 007B21A), in left arm and on 01Nov2021 at 15:45 as dose 3 (booster), single (Lot number: 939905), in left arm for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 27Nov2022, outcome "not recovered" and all described as "COVID 19 Treatment"; INTERCHANGE OF VACCINE PRODUCTS (medically significant), outcome "unknown". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (27Nov2022) Positive, notes: I tested positive on 27Nov2022; (10Dec2022) Positive, notes: tested positive again on 10Dec2022. Clinical details: It was reported, the patient tested positive on 27Nov2022 and started Paxclovid (Lot number: GF3197) on 28Nov2022 to 03Dec2022. Then tested positive again on 10Dec2022 07:00 AM. No other medication in 2 weeks. Patient was not recovered and No treatment received.   Therapeutic measures were taken as a result of drug ineffective, covid-19.  No follow-up attempts are possible. No further information is expected.
Vaccinated on 4/2/21 and 4/23/21. Covid positive on 7/27/21. Runny nose, headache, sinus pressure, loss of taste and smell since 7/27/21
This spontaneous report was received from a nurse practitioner via company representative refers to a male patient of unknown age. There were no concomitant medications, concurrent conditions and medical history reported. On an unknown date, the patient was vaccinated with ZOSTAVAX 0.65 ml, once, subcutaneous (site of administration, lot and expiration date were not reported). On an unknown date, two weeks later, the patient returned to the doctor's office with a severe shingles rash. The patient sought medical attention. He was given unspecified antivirals to treat the rash. The outcome of the event was unknown. The relatedness between the event and ZOSTAVAX was not reported. Additional information has been requested.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a contactable reporter (Consumer or other non HCP). The reporter is the patient.  A 65-year-old male patient received BNT162b2 (PFIZER/BIONTECH COVID-19 VACCINE), on 23Feb2021 as dose 1, single (Batch/Lot number: unknown), in left arm, on 16Mar2021 as dose 2, single (Batch/Lot number: unknown), in left arm, on 26Sep2021 as dose 3 (booster), single (Batch/Lot number: unknown), in left arm and on 13May2022 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 65 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Multiple sclerosis" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Jun2022, outcome "unknown" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Unknown Results, notes: COVID 19 Treatment. Therapeutic measures were taken as a result of drug ineffective, covid-19 and included treatment with Paxlovid.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Fever up to 106 degrees; severe headache; optical migraines; aches; chills; difficulty breathing; vein under right arm dropped down and unable to lift right arm more than 30 degrees; intense leg cramps... this lasted until May 5 around 5 PM. Vein under my right arm stayed descended for 3 days and slowly returned and mobility returned. Continued leg cramps, exhaustion for weeks... saw Dr. (my family physician) on Aug 10th to address continued fatigue and leg cramps. DId EKG in the office and referred for a heart scan which was conducted September 10th. Blood work was also run. All tests were normal. Took baby aspirin for leg cramps and was able to stop this in December of 2021. Fatigue has worsened over time.
had a serious lymphoma type reaction. It is very painful; had a serious lymphoma type reaction. It is very painful; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from medical information team.  A patient (no qualifiers provided) received BNT162b2 (BNT162B2), in Apr2022 as dose number unknown (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Primary Immunization series completed; MANUFACTURER UNKNOWN), for COVID-19 Immunization; Covid-19 vaccine (first BOOSTER dose; MANUFACTURER UNKNOWN), for COVID-19 Immunization. The following information was reported: LYMPHOMA (medically significant), PAIN (non-serious) all with onset 2022, outcome "unknown" and all described as "had a serious lymphoma type reaction. It is very painful".  Clinical information: On Apr2022 patient received the Pfizer Booster (second) Covid vaccination and patient have had a serious lymphoma type reaction. It was very painful, and patient do not know what to do about it. Patient thought this need to be informed, because there seems to be some opinions that this was not happening. Patient wanted to know it was happening, and at least it should be some of the information given at the time the Covid booster vaccinations are given.   The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
At the pharmacy, I requested the Pharmacist to take vaccination to Whooping for whooping cough I had on the passed, she gave me Adacel injection the next day I had Fever up to 104F kept taken Tylenol then lately switch to Motrin IB to lower the Fever temporarily with lite headache. Up to Today I still having the Problem. Found out I taken many Vaccination on 2 months,the pharmacist she Fault to advice me to let at least 1 month between Vaccination.
Shoulder began to hurt, or have soreness when I would try to lift up my two-year old, or take shirt off at the end of the day, etc. Last week it felt like it was subsiding, but this past weekend the soreness is still there..when I tried to sweep, rake, stretch, etc. I took IBProfen, which seemed to help, but not solve. I have never experienced a reaction from past flu shots.
Shingles; Itching; Rash / Rash on back; Pain in lower chest on the left side; Burning; This case was reported by a consumer via call center representative and described the occurrence of shingles in a 74-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 22nd July 2019, the patient received the 1st dose of Shingrix (intramuscular). On 23rd July 2019, 1 days after receiving Shingrix, the patient experienced shingles, pruritus, rash, chest pain and burning skin. The patient was treated with valaciclovir hydrochloride (Valtrex), lidocaine hydrochloride (Lidocaine) and gabapentin. On an unknown date, the outcome of the shingles, pruritus, rash, chest pain and burning skin were not recovered/not resolved.   It was unknown if the reporter considered the shingles, pruritus, rash, chest pain and burning skin to be related to Shingrix.  Additional case details were reported as follows: This case was reported by the patient's wife. The patient received vaccine in left arm. The next day after vaccination the patient started experiencing pain in his lower chest on the left side. It became itchy, then broke out into a rash.  On saturday, 27th July 2019, patient went to the emergency room and was diagnosed with shingles. The rash extended from the center of his chest and all the way around to his back. The reporter stated that patient getting a rip roaring case of shingles from just having the first vaccine of the new shingles shot. The patient had been prescribed with Valtrex, gabapentin and lidocaine patches. The reporter gave permission to follow up. In the XML document outcome of events was reported as recovering, but in Argus its mentioned as not recovered, so kept as reported in Argus.
Patient received 2nd dose of Moderna Covid19 vaccine on 2/5/21. Developed headaches on 2/21/21 and went for covid19 PCR test on 2/22/21 at the urgent care. On 2/22 she had headaches and chest pressure with palpitations. PCR test was reported positive on 2/23/21. Patient had virtual visit with me on 2/26/21 and reported persistent headaches but was clinically stable.
Pt arrived home after receiving vaccine and later that day began experiencing extreme weakness in both LE. After 2 days, pt. developed rhabdomyolysis, was hospitalized, and treated. She recovered and was sent for 1 month of inpatient rehab. for continued LE weakness.
Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) in a 47-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 31-Mar-2021 at 4:03 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 31-Mar-2021 at 4:03 PM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The age of the patient was reported as 47.99.  No concomitant medications were reported.  On 31-Mar-2021, 14 vials were moved to clinic.   The vial was initially moved to the fridge on 30-Mar-2021 and proposed beyond use date was 29-Apr-2021.   On the date of administration, at 08:00 AM to 09:00 A.M., the temperature recorded was 32 degree Fahrenheit has been reached by the vial. The vial was moved to clinic on 31-Mar-2021.  The vials were only punctured right before administration and all doses were drawn from the vial due to high-pace clinic.  The healthcare professional (HCP) reported that, each time a vial was put into a cooler, sometimes there was a period of time of 1 hour or 1 hour and a half approximately, when temperature data logger registered a temperature of 34- or 35-degree Fahrenheit. The vial was stored in cooler storage during high-pace COVID-19 vaccination clinic at the time of excursion. Temperature recordings were taken using a Fisherbrand traceable temperature monitor at every hour.  The vial was not in a frozen state at the time of vaccine administration.  After administration, the vial was returned to the freezer/refrigerator, or maintained at room temperature.  No treatment information was provided.  The occupation of reporter was reported as clinic manager.   This case was linked to MOD-2022-566976 (Patient Link).
duration started on 1/15/21- current symptoms include, swollen left eye, numbness to left arm, fatigue , loss of hearing, chills
1 day after the 2nd dose of vaccine, began experiencing symptoms of diarrhea, vomiting, which persisted for about 2 weeks. Had severe lasting migraines for 2 months, had issues with chest pressure, heart palpitations on and off for the first 2 months as well. After the initial 2 weeks of diarrhea and vomiting, still had occasional episodes of nausea and diarrhea. Chronic fatigue developed. Went to see cardiologist for chest pressure and palpitations and had an EKG done, was told the symptoms were likely linked to the COVID vaccine. EKG was slightly different from pre-vaccine, but no significant changes. Advised to continue monitoring heart symptoms, and go to ER if symptoms became more severe. Went to pulmonologist for same symptoms, and gastroenterologist for GI issues, all concluded that they were vaccine side effects and advised to go to ER. Did not change anything at the time, did not take any new prescribed medications (none were prescribed at the time). Some symptoms began to resolve (GI issues), however, the chronic fatigue is still there, although it is slightly improved. Occasional chest palpitations have occurred since then. The major concern is that I developed blood clots recently (unclear if it is related to the vaccine at this time). Put on prescribed blood thinners and aspirin, and is being closely monitored. Notably, I do not have a family history of blood clotting, and I have had multiple surgeries with no issues with blood clotting.  In July, the time of the first blood clot was given xarelto 20 mg for 30 days, then aspirin 81 mg once a day, now back on xarelto 10 mg indefinitely because I had a second blood clot incident in September. Given the closeness of blood clot incidents and other conditions (pulmonary issues, heart issues, hypertension, diabetes, etc.).
Patient asked for location of water fountain. Patient arose, walked to water fountain, returned to chair and then advised not feeling well, then fainted and nonresponsive. Mother advised "sister faints with shots and does not do well". Patient's bilateral hands clenched and in posturing position, color in face and lips pale. Patient responded to ammonia inhalant placed near nostrils. Patient continued to be groggy and slow to respond. Pulse weak and slow. Placed patient in Trendelenburg position. Color returned to patient's face and lips. Patient fully alert and responsive 15 post incident minutes.
worsening of ringing in her ears/high and constant ringing; This is a spontaneous report from a contactable consumer (patient). A 75-year-old female patient received first dose of BNT162B2(PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Batch/Lot number: unknown), via an unspecified route of administration on 26Jan2021 at 13:30 into left arm as a single dose for COVID-19 immunization. Medical history included tinnitus. The patient's concomitant medications were not reported. Prior the vaccination, patient did not receive any other vaccine within four weeks. On 26Jan2021, patient experienced a worsening of ringing in her ears/ high and constant ringing. She described it as louder and constant. she already had "ringing of the ears" or "tinnitus" prior to receiving the vaccine. she has read information stating that it might be okay to receive the second dose of the Pfizer COVID-19 vaccine up to 6 weeks after the first dose. Patient stated that she has two things, first she had the first dose of the Pfizer COVID 19 vaccine and then she had ringing in her ears, which she has anyway, but this was at a high and constant level. She is asking will this get worse with the second dose. Adds it is pretty loud. She is scheduled for the second dose on 16Feb2021.Adds she is sensitive to drugs, not allergic, but when they say we could go for six weeks, if she might have less side effects she would rather wait. She is wondering if that would be beneficial for her to wait to six weeks? Adds this is all very confusing. Patient was not visited to physician or Emergency Room for the event. The outcome of the event was not recovered.  Follow-up attempts are completed. No further information is expected.
10/29/13 Pt phined the office and stated she thinks she has a rash down her arm as a reslt of the flu injection given 10/22/13. Dr. notified and orders given to pt to take Benadryl during the night and Claritin during the day. If no improvement by 10/31/13 Pt. instructed to call the clinic and she will be seen. 11/15/13 a slight rash "all over and is wondering if it is from the flu shot 11/22/13 Phone call made to CDC re: if pts rash may poss be from the influenza vaccine given on 10/22/13. Pt. reported initial rash to arm injection was given, on 10/29/13, however pt states that rash actually started within about 4 days after the injection. CDC stated that it would probably be a good idea to report this to VAERS (vaccine adverse event reporting system) for tracking purposes, as there were 300 million of these vaccines given and any data that may be associated with an adverse event within 42 days of the vaccine should be reported. Pt. notified and aware that I will be filing this report and was in agreement with doing so. DCO will also be notified of such action. When I spoke with pt. today, she states that the rash seems to be subsiding. (when I saw her last Friday it was a very fine scattered macular generalized non-puritic rash.)   12/2/2013 Phoned patient and she states rash is almost completely gone.
This spontaneous report as received from licensed practical nurse refers to a patient of unknown age and gender. On 18-FEB-2014 the patient was inadvertently vaccinated with ZOSTAVAX (strength, dose unit and route unknown) single dose with lot # H013945 that had expired on 25-OCT-2013, subcutaneously. No adverse effects reported. The outcomes of inadvertently administered ZOSTAVAX that had expired and no adverse effect reported was unknown. No further information provided. Additional information has been requested.
Patient requested to be laying down on stretcher during vaccination due to prior dizziness episodes related to vaccines. Patient BP 98/57, HR83, RR21. Given orange juice and water, discharged in stable condition
This spontaneous report received from pharmacist refers to 75 year old female patient with no drug reactions or allergies and no pertinent medical history who on 01-DEC-2014 was vaccinated with a dose of ZOSTAVAX (lot # K010630, expiration date 30-OCT-2015) (dose and route were not reported). There was no concomitant therapy. On 28-DEC-2014 the patient developed a small rash on her face which patient believed it to be a small outbreak of shingles but the patient's physician had not confirmed that it was shingles. No treatment was given. No laboratories diagnostic tests were performed. The patient sought medical attention saw a physician. At the time of the report the outcome of rash was unknown. Additional information has been requested.
red; rash; ITCHY; hardness; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE ERYTHEMA (red), INJECTION SITE RASH (rash), PRURITUS (ITCHY) and INJECTION SITE INDURATION (hardness) in an 80-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041LZ019) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Jan-2021, the patient experienced INJECTION SITE ERYTHEMA (red), INJECTION SITE RASH (rash), PRURITUS (ITCHY) and INJECTION SITE INDURATION (hardness). At the time of the report, INJECTION SITE ERYTHEMA (red), INJECTION SITE RASH (rash), PRURITUS (ITCHY) and INJECTION SITE INDURATION (hardness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment information was provided.
Shivering like crazy; Fatigued; Sore arm at the injection site; Fever; This spontaneous case was reported by a nurse and describes the occurrence of INJECTION SITE DISCOMFORT (Sore arm at the injection site), PYREXIA (Fever), CHILLS (Shivering like crazy) and FATIGUE (Fatigued) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Anemia on 12-Oct-1958, Palpitations (cardiac palpitations) on 06-Feb-1970 and Dry eyes on 14-Aug-2018. Concurrent medical conditions included Drug allergy (allergic to sulfa). Concomitant products included ESTRADIOL (ESTROGEN) from 01-Jul-2015 to an unknown date, PROGESTERONE and TESTOSTERONE from 01-Jul-2015 to an unknown date for Menopause, MULTIVITAMINS [VITAMINS NOS] and FISH OIL for an unknown indication.   On 11-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 2 dosage form. On 12-Feb-2021, the patient experienced INJECTION SITE DISCOMFORT (Sore arm at the injection site) and PYREXIA (Fever). On an unknown date, the patient experienced CHILLS (Shivering like crazy) and FATIGUE (Fatigued). At the time of the report, INJECTION SITE DISCOMFORT (Sore arm at the injection site) outcome was unknown and PYREXIA (Fever), CHILLS (Shivering like crazy) and FATIGUE (Fatigued) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   This case was linked to MOD-2021-008207 (Patient Link).   Reporter did not allow further contact
SWELLING ON TRAPEZIUS BETWEEN NECK AND SHOULDER. NO RASH OR PAIN, JUST "GEL-LIKE" SWELLING.
Info has been recvd from a registered nurse. On 12/14/00, pt recvd vax. On 12/15/00, pt experienced raised rash from shoulder to elbow. The pt did not have any pain, fever or swelling. Subsequently, as of 12/19/00, pt's symptoms were almost completely resolved. No follow-up, work-up or hospitalization was necessary. Unspecified medical attention was sought. No further info is expected.